Hikal Limited Q2 FY27 Earnings: ₹434 Cr Revenue, ₹45 Cr EBITDA, CDMO Contract Signed
Hikal · Pharmaceuticals & Biotechnology
Key highlights
- Q2 FY27 revenue ₹434 crore, EBITDA ₹45 crore, PAT ₹(6) crore; Pharmaceuticals ₹278 crore, Crop-Protection ₹156 crore
- Signed multi-year CDMO contract with Europe-based global agrochemical company for specialized product supply
- Bengaluru API facility received Swissmedic GMP certification; Personal Care commercial production commenced at Panoli facility
Why it's rated major development: the year-on-year change is 83% (50% or more)
Figures checked against the filing by a second AI read. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Hikal
- Order winNotableHikal Signs Multi-Year Global CDMO Contract with Leading Agrochemical Company
- Capex / expansionNotableHikal Limited launches new cGMP Panoli facility for Personal Care production
Other order win filings this fortnight
- LCC Projects Limited receives ₹703 crore LOI from Gujarat Water Supply and Sewerage Board
- Man Infraconstruction secures two EPC work orders aggregating ₹583 crore
- Sunita Tools Limited receives supply contract for M1 shell forging (6,000 sets)
- Sunita Tools Limited receives OEM qualification and order for forging empty shells
- Garden Reach Shipbuilders & Engineers signs ₹32,000 Crore Indian Navy contract for 5 NGCs
- GRSE signs ₹32,000 crore contract for five Next Generation Corvettes with Indian Navy
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.